Servier, Black Diamond Therapeutics in Global Licensing Agreement for Targeted Oncology Therapy

 

• The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology
• Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancer
• Black Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments
  plus royalties

https://www.globenewswire.com/news-release/2025/03/19/3045227/0/en/Servier-and-Black-Diamond-Therapeutics-Announce-Global-Licensing-Agreement-for-BDTX-4933-A-Targeted-Oncology-Therapy.html